Intravitreal Bevacizumab vs Laser vs Combination of Bevacizumab and Modified Laser in PDR
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
In this randomized 3-armed clinical trial, 105 eyes with PDR will be included and divided
randomly into 3 groups: IVB group (35 eyes) that receive 4 monthly IVB injections and then
rescue IVB, PRP group (35 eyes) that undergo full PRP in 2 or 3 sessions and then rescue IVB,
and combination group (35 eyes) that receive 2 bimonthly IVB injections and a modified laser
(1 session anterior to the equator) and then rescue IVB or laser. Diabetic macular edema
(DME) will be treated independently in all groups by IVB. Primary outcome will be the number
and activity of neovascularizations at 4,8 and 12 months and secondary measures will be
changes in best corrected visual acuity (BCVA) and central macular thickness (CMT), and
number of examinations and injection.